Semaglutide shows benefit for HFpEF patients with obesity

  • Fozia Ahmed

Press/Media: Research

Period25 Aug 2023

Media coverage

5

Media coverage

  • TitleOzempic and Wegovy can reverse heart disease symptoms: Slimming jabs offer hopes of cure as study suggests key ingredient semaglutide is three times more effective than existing treatments
    Media name/outletMail online
    Media typeWeb
    Country/TerritoryUnited Kingdom
    Date25/08/23
    DescriptionWeight loss jabs can reverse symptoms of heart disease in a major breakthrough offering hope to half a million Britons.

    A landmark global trial found semaglutide - known under brand names Ozempic and Wegovy – was three times more effective than any existing treatments for heart failure.

    Experts said the new class of weight-loss drugs will herald a ‘new era’, transforming the lives of patients with the deadly disease.
    URLhttps://www.dailymail.co.uk/health/article-12445167/Ozempic-Wegovy-reverse-heart-disease-symptoms.html
    PersonsFozia Ahmed
  • TitleWeight-loss drug Wegovy produces ‘largest benefitever seen’ for patients with most common form of heartfailure, trial finds
    Media name/outletCNN
    Country/TerritoryUnited States
    Date25/08/23
    DescriptionA study found that a 2.4-milligram weekly dose of semaglutide, sold as Wegovy for weightloss, led to an improvement of 17 points on a 100-point scale that’s used to assesssymptoms of a condition known as heart failure with preserved ejection fraction.
    URLhttps://edition.cnn.com/2023/08/25/health/wegovy-semaglutide-heart-failure/index.html
    PersonsFozia Ahmed
  • TitleWeight-loss drug can reverse heart failure symptoms, study finds
    Media name/outletThe Guardian
    Country/TerritoryUnited Kingdom
    Date25/08/23
    DescriptionSemaglutide injections trigger ‘very large improvements’ in patients with hearts too stiff to fill properly
    URLhttps://www.theguardian.com/society/2023/aug/25/weight-loss-drug-semaglutide-reverses-heart-failure-symptoms-study
    PersonsFozia Ahmed
  • TitleWegovy Scores HFpEF Benefits in People With Obesity
    Media name/outletMedscape
    Country/TerritoryUnited States
    Date25/08/23
    DescriptionAdults with heart failure with preserved ejection fraction (HFpEF) but without diabetes showed significant improvements in their heart failure-related symptoms and physical limitations, exercise function, and weight loss when treated with a weight-reducing dose of semaglutide for 52 weeks compared with placebo in the randomized STEP-HFpEF trial.
    URLhttps://www.medscape.com/viewarticle/995844?form=fpf
    PersonsFozia Ahmed
  • Titlehttps://www.thetimes.co.uk/article/weight-loss-injections-ozempic-could-be-key-curing-heart-failure-5cbgx6x88
    Media name/outletThe Times
    Country/TerritoryUnited Kingdom
    Date25/08/23
    DescriptionWeight loss injections are three times more effective than any previous drug at treating heart failure, a landmark trial has found.

    The new generation of anti-obesity drugs offer hope of the first cure for heart failure, a debilitating condition that affects one million people in Britain.
    URLhttps://www.thetimes.co.uk/article/weight-loss-injections-ozempic-could-be-key-curing-heart-failure-5cbgx6x88
    PersonsFozia Ahmed